Stocks · News reference
AIM ImmunoTech Announces Final Subjects Receives Last Dose Of Ampligen Under Study Protocol In Phase 2 DURIPANC Clinical Study
AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the final subject has received their last dose of Ampligen® (rintatolimod) under the study protocol, reaching this milestone
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 3, 2026, 12:41 PM
- Checked
- Aug 3, 2026, 12:41 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — AIM ImmunoTech Inc. (AIM)
Filed: 2026-08-11 AccNo: 0001493152-26-036996 Size: 609 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgarAIM ImmunoTech Q2 EPS $(0.43) Misses $(0.18) Estimate, Sales $26.000K Up From $25.000K YoY
AIM ImmunoTech (AMEX:AIM) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.18) by 138.89 percent. This is a 88.32 percent increase over losses of $(3.68) per share from
Read original at benzinga